{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T12:51:43Z","timestamp":1791118303873,"version":"4.1.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Heart Failure Clinics"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1016\/j.hfc.2011.11.001","type":"journal-article","created":{"date-parts":[[2011,12,14]],"date-time":"2011-12-14T14:43:42Z","timestamp":1323873822000},"page":"247-253","source":"Crossref","is-referenced-by-count":6,"title":["The Role of Mineralocorticoid Receptor Antagonists in Patients with American College of Cardiology\/American Heart Association Stage B Heart Failure"],"prefix":"10.1016","volume":"8","author":[{"given":"Bertram","family":"Pitt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hfc.2011.11.001_bib1","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1161\/CIRCULATIONAHA.106.653964","article-title":"Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure","volume":"115","author":"Guder","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2011.11.001_bib2","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2011.11.001_bib3","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2011.11.001_bib4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2011.11.001_bib5","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1161\/01.CIR.0000138680.89536.A9","article-title":"Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure","volume":"110","author":"Mottram","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2011.11.001_bib6","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.108.778811","article-title":"Serum potassium and clinical outcomes in the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS)","volume":"118","author":"Pitt","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2011.11.001_bib7","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1093\/eurheartj\/ehq019","article-title":"Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study","volume":"31","author":"Tomaschitz","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hfc.2011.11.001_bib8","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.ahj.2010.06.049","article-title":"Rationale for an early aldosterone blockade in acute myocardial infarction and design of the albatross trial","volume":"160","author":"Beygui","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.hfc.2011.11.001_bib9","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2008.11.013","volume":"53","author":"Hunt","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hfc.2011.11.001_bib10","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.HYP.0000259805.18468.8c","article-title":"Effect of spironolactone\u00a0on blood pressure in subjects with\u00a0resistant hypertension","volume":"49","author":"Chapman","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.hfc.2011.11.001_bib11","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1161\/01.HYP.27.5.1039","article-title":"Changes in left ventricular anatomy and function in hypertension and primary aldosteronism","volume":"27","author":"Rossi","year":"1996","journal-title":"Hypertension"},{"key":"10.1016\/j.hfc.2011.11.001_bib12","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1161\/01.CIR.0000091405.00772.6E","article-title":"Effects of eplerenone, enalapril, and eplerenone\/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-Left Ventricular Hypertrophy study","volume":"108","author":"Pitt","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2011.11.001_bib13","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1161\/HYPERTENSIONAHA.107.103267","article-title":"Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients","volume":"51","author":"Savoia","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.hfc.2011.11.001_bib14","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/HJH.0b013e32834103d4","article-title":"Role of plasma aldosterone concentration in regression of left-ventricular mass following antihypertensive medication","volume":"29","author":"Yoshida","year":"2011","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.hfc.2011.11.001_bib15","doi-asserted-by":"crossref","first-page":"4828","DOI":"10.1210\/en.2002-220120","article-title":"Selective aldosterone blockade prevents angiotensin II\/salt-induced vascular inflammation in the rat heart","volume":"143","author":"Rocha","year":"2002","journal-title":"Endocrinology"},{"key":"10.1016\/j.hfc.2011.11.001_bib16","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1053\/euhj.1998.1099","article-title":"Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients","volume":"19","author":"Duprez","year":"1998","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hfc.2011.11.001_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0008-6363(00)00092-4","article-title":"Renin-angiotensin-aldosterone system and myocardial fibrosis","volume":"47","author":"Brilla","year":"2000","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.hfc.2011.11.001_bib18","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1161\/01.CIR.102.22.2700","article-title":"Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized Aldactone Evaluation Study (RALES). RALES investigators","volume":"102","author":"Zannad","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2011.11.001_bib19","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1161\/CIRCULATIONAHA.106.638569","article-title":"Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction","volume":"115","author":"Martos","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2011.11.001_bib20","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S0002-9149(00)00729-3","article-title":"Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy","volume":"85","author":"Ramires","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hfc.2011.11.001_bib21","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1097\/HJH.0b013e3282e9a72d","article-title":"Spironolactone has antiarrhythmic activity in ischaemic cardiac patients without cardiac failure","volume":"25","author":"Shah","year":"2007","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.hfc.2011.11.001_bib22","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1749-6632.2002.tb04415.x","article-title":"The pathophysiology of aldosterone in the cardiovascular system","volume":"970","author":"Rocha","year":"2002","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.hfc.2011.11.001_bib23","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1161\/01.HYP.0000154365.30593.d3","article-title":"Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src","volume":"45","author":"Callera","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.hfc.2011.11.001_bib24","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.amjhyper.2003.10.007","article-title":"Mice lacking osteopontin exhibit increased left ventricular dilation and\u00a0reduced fibrosis after aldosterone infusion","volume":"17","author":"Sam","year":"2004","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.hfc.2011.11.001_bib25","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1172\/JCI41080","article-title":"Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice","volume":"120","author":"Usher","year":"2010","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.hfc.2011.11.001_bib26","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1161\/CIRCRESAHA.108.188995","article-title":"Acquisition of brain Na sensitivity contributes to salt-induced sympathoexcitation and cardiac dysfunction in mice with pressure overload","volume":"104","author":"Ito","year":"2009","journal-title":"Circ Res"},{"key":"10.1016\/j.hfc.2011.11.001_bib27","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199209033271003","article-title":"Effect of enalapril on mortality and the development of\u00a0heart failure in asymptomatic patients with reduced\u00a0left ventricular ejection fractions. The SOLVD investigators","volume":"327","year":"1992","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2011.11.001_bib28","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jsbmb.2004.12.010","article-title":"RALES, EPHESUS and redox","volume":"93","author":"Funder","year":"2005","journal-title":"J\u00a0Steroid Biochem Mol Biol"},{"key":"10.1016\/j.hfc.2011.11.001_bib29","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1161\/01.HYP.0000121362.64182.ad","article-title":"Impaired 11-beta hydroxysteroid dehydrogenase type 2 activity in sweat gland ducts in human essential hypertension","volume":"43","author":"Bocchi","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.hfc.2011.11.001_bib30","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1378\/chest.06-1442","article-title":"Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension","volume":"131","author":"Pratt-Ubunama","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.hfc.2011.11.001_bib31","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S0002-9149(01)01905-1","article-title":"Effect of successful electrical cardioversion on serum aldosterone in patients with persistent atrial fibrillation","volume":"88","author":"Goette","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hfc.2011.11.001_bib32","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1097\/HJH.0b013e3282861fa4","article-title":"A\u00a0possible association between primary aldosteronism and a lower beta-cell function","volume":"25","author":"Mosso","year":"2007","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.hfc.2011.11.001_bib33","doi-asserted-by":"crossref","DOI":"10.4061\/2011\/685238","article-title":"Role of the\u00a0renin-angiotensin system and aldosterone on cardiometabolic syndrome","volume":"2011","author":"Stiefel","year":"2011","journal-title":"Int J Hypertens"},{"key":"10.1016\/j.hfc.2011.11.001_bib34","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s11906-010-0175-6","article-title":"The kidneys and aldosterone\/mineralocorticoid receptor system in salt-sensitive hypertension","volume":"13","author":"Shibata","year":"2011","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.hfc.2011.11.001_bib35","article-title":"Plasma aldosterone levels in patients with coronary artery disease (CAD) without heart failure or myocardial infarction: implications for pathophsiology, prognosis, and therapy","author":"Pitt","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hfc.2011.11.001_bib36","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nm1545","article-title":"Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity","volume":"13","author":"Leopold","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.hfc.2011.11.001_bib37","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1161\/01.CIR.0000015854.60710.10","article-title":"Mineralocorticoid receptor antagonism in experimental atherosclerosis","volume":"105","author":"Rajagopalan","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2011.11.001_bib38","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1161\/01.CIR.0000127949.05756.9D","article-title":"Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone","volume":"109","author":"Keidar","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2011.11.001_bib39","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/01.HYP.0000184640.81730.22","article-title":"Eplerenone inhibits atherosclerosis in nonhuman primates","volume":"46","author":"Takai","year":"2005","journal-title":"Hypertension"},{"issue":"4","key":"10.1016\/j.hfc.2011.11.001_bib40","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/eurheartj\/ehn543","article-title":"Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials","volume":"30","author":"Ezeckowitz","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hfc.2011.11.001_bib41","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1172\/JCI119249","article-title":"Angiotensin-independent mechanism for aldosterone synthesis during chronic extracellular fluid volume depletion","volume":"99","author":"Okubo","year":"1997","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.hfc.2011.11.001_bib42","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.ejheart.2004.04.013","article-title":"The clinical implications of aldosterone escape in congestive heart failure","volume":"6","author":"Struthers","year":"2004","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.hfc.2011.11.001_bib43","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1161\/01.HYP.0000201443.63240.a7","article-title":"Effects of aldosterone on the vasculature","volume":"47","author":"Schiffrin","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.hfc.2011.11.001_bib44","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1161\/01.RES.0000180753.63183.95","article-title":"Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells","volume":"97","author":"Min","year":"2005","journal-title":"Circ Res"},{"key":"10.1016\/j.hfc.2011.11.001_bib45","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1248\/bpb.34.61","article-title":"Spironolactone decreases isoproterenol-induced ventricular fibrosis and matrix metalloproteinase-2 in rats","volume":"34","author":"Hori","year":"2011","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.hfc.2011.11.001_bib46","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1007\/s00125-004-1510-8","article-title":"Spironolactone impairs endothelial function and heart rate variability in patients with type 2 diabetes","volume":"47","author":"Davies","year":"2004","journal-title":"Diabetologia"},{"key":"10.1016\/j.hfc.2011.11.001_bib47","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/01.CIR.101.6.594","article-title":"Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I\/angiotensin II conversion in patients with chronic heart failure","volume":"101","author":"Farquharson","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2011.11.001_bib48","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.ahj.2010.04.024","article-title":"Effect of eplerenone versus spironolactone on cortisol and hemoglobin A1(c) levels in patients with chronic heart failure","volume":"160","author":"Yamaji","year":"2010","journal-title":"Am Heart J"}],"container-title":["Heart Failure Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713611001280?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713611001280?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,27]],"date-time":"2018-11-27T20:23:25Z","timestamp":1543350205000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551713611001280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S1551713611001280"],"URL":"https:\/\/doi.org\/10.1016\/j.hfc.2011.11.001","relation":{},"ISSN":["1551-7136"],"issn-type":[{"value":"1551-7136","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]}}}